Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Portfolio Pulse from
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported its third quarter 2024 financial results and highlighted recent business developments. The company announced that 108 patients have completed a 1-year open-label extension trial for brilaroxazine, with topline data expected in December 2024. Vocal biomarker data from the RECOVER trial supports brilaroxazine's efficacy in treating schizophrenia symptoms.
November 14, 2024 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals reported Q3 2024 results and progress in its brilaroxazine trials. 108 patients completed a 1-year trial, with data expected in December 2024. Vocal biomarker data supports the drug's efficacy in treating schizophrenia.
The completion of the 1-year open-label extension trial by 108 patients and the upcoming topline data release in December 2024 are significant milestones for Reviva Pharmaceuticals. The positive vocal biomarker data from the RECOVER trial further supports the potential efficacy of brilaroxazine in treating schizophrenia, which could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100